Cargando…

Risk evaluation and monitoring in multiple sclerosis therapeutics

BACKGROUND: Risk for multiple sclerosis (MS) disease-modifying therapies (DMT) must be assessed on an ongoing basis. Early concerns regarding the first-approved DMTs for MS have been mitigated, but recently licensed therapies have been linked to possibly greater risks. OBJECTIVES: The objective of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clanet, Michel C, Wolinsky, Jerry S, Ashton, Raymond J, Hartung, Hans-Peter, Reingold, Stephen C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2014
Materias:	Meeting Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232326/ https://www.ncbi.nlm.nih.gov/pubmed/24293456 http://dx.doi.org/10.1177/1352458513513207

Ejemplares similares

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
por: Polman, Chris H, et al.
Publicado: (2011)

Cell-based therapeutic strategies for multiple sclerosis
por: Scolding, Neil J, et al.
Publicado: (2017)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications
por: Zanghì, Aurora, et al.
Publicado: (2022)

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

Viral etiology of multiple sclerosis: where does the truth lie?
por: Waksman, Byron H., et al.
Publicado: (1986)

Pregnancy, sex and hormonal factors in multiple sclerosis
por: Miller, David H, et al.
Publicado: (2014)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France
por: Pivot, Diane, et al.
Publicado: (2016)

Vision and vision-related outcome measures in multiple sclerosis
por: Balcer, Laura J., et al.
Publicado: (2015)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Animal models of multiple sclerosis—Potentials and limitations
por: Mix, Eilhard, et al.
Publicado: (2010)

Improving the efficiency of clinical trials in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

EHMTI-0080. How migraine is affected by therapies for multiple sclerosis
por: Condello, C, et al.
Publicado: (2014)

Aggressive multiple sclerosis (2): Treatment
por: Arrambide, Georgina, et al.
Publicado: (2020)

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
por: Wolinsky, Jerry S, et al.
Publicado: (2020)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls
por: Alpérovitch, A., et al.
Publicado: (1991)

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
por: Krajnc, Nik, et al.
Publicado: (2022)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Panic disorder as presenting symptoms of multiple sclerosis
por: Algin, Demet İlhan, et al.
Publicado: (2010)

Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis
por: Vasileiou, Eleni S., et al.
Publicado: (2022)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

The Molecular Basis for Remyelination Failure in Multiple Sclerosis
por: Gruchot, Joel, et al.
Publicado: (2019)

Assessing heterogeneity of treatment effect in multiple sclerosis trials
por: Sormani, Maria Pia, et al.
Publicado: (2023)

Enhancing diversity of clinical trial populations in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2017)

Audit of therapeutic drug monitoring of dosing of vancomycin on an intensive care unit
por: Mason, P, et al.
Publicado: (2002)

Intermediate outcomes for clinical trials of multiple sclerosis rehabilitation interventions: Conceptual and practical considerations
por: Finlayson, Marcia, et al.
Publicado: (2023)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

EHMTI-0028. Occipital neuralgiform pain as multiple sclerosis relapse
por: Ozerden, M, et al.
Publicado: (2014)

Aggressive multiple sclerosis (1): Towards a definition of the phenotype
por: Iacobaeus, Ellen, et al.
Publicado: (2020)

Enhancing involvement of people with multiple sclerosis in clinical trial design
por: Gray, Emma, et al.
Publicado: (2023)

Multiple Myeloma: Risk Stratification and Toxicity Management
por: Richards, Tiffany, et al.
Publicado: (2018)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients—A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness
por: Ehler, Johannes, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bovcmgau22rbegn6l1fp9lpn1m